Skip to main content

Neurodegenerative disease biomarkers based on high quality wireless EEG.

Objetivo

The need: Today, although over 6M people suffer from Parkinson's and related diseases worldwide we have no objective early diagnostic test. By the time patients present the symptoms that lead to diagnosis the disease is already very advanced and the options for treatment extremely limited. This has an enormous impact on cost of care and an even greater impact on patient and carer quality of life. An early diagnostic test will revolutionise treatment in terms of slowing disease evolution and improved outcomes, with fewer years in the advanced phases of the disease requiring expensive full-time care.
Our goal: We aim to commercialise non-invasive, very low-cost preclinical electroencephalograph (EEG) biomarkers for synucleinopathies (Parkinson Disease - PD and Lewy Body Dementia - LBD), which will have real impact on both quality of life and cost of care.

Ámbito científico

  • /ciencias médicas y de la salud/medicina básica/neurología/parkinson

Convocatoria de propuestas

H2020-SMEINST-1-2014
Consulte otros proyectos de esta convocatoria

Régimen de financiación

SME-1 - SME instrument phase 1

Coordinador

STARLAB BARCELONA SL
Dirección
Avenida Tibidabo 47 Bis
08035 Barcelona
España
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Aportación de la UE
€ 50 000